Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tolperisone - Sanochemia Pharmazeutika

Drug Profile

Tolperisone - Sanochemia Pharmazeutika

Alternative Names: Agileo; AV-650; Instant release (IR) tolperisone tablets - Sanochemia; SPH-3047; Sustained release tolperisone tablets - Sanochemia; Tolcare; Viveo

Latest Information Update: 27 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sanochemia Pharmazeutika
  • Developer Neurana Pharmaceuticals; Sanochemia Pharmazeutika
  • Class Analgesics; Antispasmodics; Antispastics; Muscle relaxants; Propiophenones; Pyridines; Small molecules
  • Mechanism of Action Calcium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Muscle hypertonia; Muscle spasticity
  • Phase II Back pain
  • No development reported Spasm

Most Recent Events

  • 23 Sep 2019 Efficacy and adverse event data from a phase II STAR trial in Back pain (associated with muscle spasm) released by Neurana Pharmaceuticals
  • 12 Jul 2019 Neurana Pharmaceuticals completes a phase II trial in Back Pain (associated with muscle spasm) in USA (NCT03802565)
  • 17 Jun 2019 Neurana Pharmaceuticals completes enrolment in the STAR study phase II trial for Back pain (associated with muscle spasm) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top